Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
2026-01-09
Compare the pharmacokinetics of CBD and THC via the sublingual route to the oro-pharyngeal route.
"Comparison of the sublingual and oro-pharyngeal routes showed no statistically significant difference in THC or CBD pharmacokinetic parameters other than an earlier Tmax following sublingual dosing." (Guy) (Tmax represents the time elapsed from drug administration to peak plasma concentration.)Guy, G. W., & Robson, P. J. (2004). A phase I, open-label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis-based medicine extract (CBME) administered on three different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). Journal of Cannabis Therapeutics, 3(4), 79-120. https://doi.org/10.1300/J175v03n04_01
2026-01-08
What dose of THC will likely cause psychotropic effects? What dose will likely cause marked intoxication?
"A dose of 0.15 to 0.30 mg/kg THC (ie, an individual oral dose of 10-20 mg THC) appears to be sufficient to achieve psychotropic effects, and a dose of 0.45 to 0.6 mg/kg of THC (ie, an individual oral dose of 30-40 mg of THC) should produce marked intoxication." Page, R. L., Allen, L. A., Kloner, R. A., Carriker, C. R., Martel, C., Morris, A. A., Piano, M. R., Rana, J. S., Saucedo, J. F., & American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation, 142(10), e131-e152. https://doi.org/10.1161/CIR.0000000000000883
2026-01-07
What lifestyle factors affect the density/expression of CB1 receptors?
The density/expression of CB1 receptors may be affected by lifestyle factors, such as diet, exercise, stress and consumption of cannabis or synthetic cannabinoids. (Long term cannabis use leads to downregulation of CB1 receptors in the brain, and this downregulation leads to tolerance.) Gorelick, D. A. (2023). Cannabis-related disorders and toxic effects. The New England Journal of Medicine, 389, 2267-2275. https://doi.org/10.1056/NEJMra2306065 and Wilson, G., Yang, L., Su, X., Ding, S., Li, L., Yang, Y., Wang, X., Wang, W., Sa, Y., Zhang, Y., Chen, J., & Ma, X. (2023, October 31). Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: Review. Pharmacological Reports.
2026-01-06
Is the extent of absorption of CBD impacted by the co-administration of food?
Yes, the co-administration of CBD with a high-fat meal significantly increases the absorption of CBD compared to ingesting CBD under fasting conditions or co-administration with a high-carbohydrate meal. In fact, according to studies evaluating the metabolism of Epidiolex, consuming CBD with fatty foods may increase the blood levels of CBD by as much as 4-5 times. Cunha, M. F. D., Funnell, M. P., Johnson, D. A., Nickels, M., Bailey, S. J., Heaney, L. M., & James, L. J. (2025). A prior high-fat meal increases plasma cannabidiol concentrations compared to an isoenergetic high-carbohydrate meal in healthy young participants: A randomised crossover study. Proceedings of the Nutrition Society, 84(OCE4), E254.
Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770-1804. https://doi.org/10.1002/cbdv.200790152
Welty, T. E., Chapman, K. E., Faught, R. E., & Kotloski, R. J. (2019). American Epilepsy Society (AES): Written comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): On Docket ID# FDA-2019-N-1482, scientific data and information about products containing cannabis or cannabis-derived compounds; public hearing; request for comments: Submitted on July 16, 2019. Epilepsy Currents, 19(6), 361-368. https://doi.org/10.1177/1535759719878716
2026-01-05
Are marijuana and most cannabis-derived compounds classified as Schedule I controlled substances? If so, why?
According to the US Federal Government's Controlled Substances Act (CSA), marijuana and most cannabis-derived compounds remain classified as Schedule I controlled substances (at the FEDERAL level) because they have a high potential for abuse and lack an accepted medical use. CBD products that do NOT contain more than 0.3% __-tetrahydrocannabinol (THC) on a dry weight basis meet the definition of hemp and therefore are not Schedule I substances. Controlled Substances Act, 21 U.S.C. §§ 801-971. https://www.govinfo.gov/content/pkg/USCODE-2014-title21/html/USCODE-2014-title21-chap13-subchapI.htm
Learn something every day™ in your 
feed…
Our courses
CBD in Clinical Care V2
A Nationally Approved CME/CE Medical Marijuana Course V2
Cannabis Essentials CME/CE Bundle
New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.